ASH 2022: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
Primary refractory young myeloma: a difficult clinical situation - YouTube
Sequencing BCMA-targeted agents in multiple myeloma | VJHemOnc
Post-Congress webinars – International Academy for Clinical Hematology (IACH)
Genomic Studies Have Identified Multiple Mechanisms of Genetic Changes in Waldenström Macroglobulinemia
ASH 2022: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results - ScienceDirect
Irene Ghobrial, MD - Home | Facebook
Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis
Study shows that immune system holds clues to patients with high-risk smoldering myeloma likely to benefit from treatment - Dana-Farber Cancer Institute | Boston, MA
Dr. Karma Salem, MD – Atlanta, GA | Radiology
Immunomodulator Drug-Based Therapy in Myeloma and the Occurrence of Thrombosis
Study Shows That Immune System Holds Clues to Patients With High-Risk Smoldering Myeloma Likely to Benefit From Treatment - BroadcastMed
Dr. Amir Yosef, MD | Mankato, MN | Oncologist | US News Doctors
Forimtamig's Effect on T-cells in Relapsed Myeloma Patients
PDF) Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience
ASH 2022: Multiple Myeloma Highlights - The ASCO Post
Dr. Luke Whitesell, MD – Cambridge, MA | Pediatric Hematology & Oncology
Knowing and Finding the enemy - Roswell Park Comprehensive Cancer Center
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant | Nature Communications
Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma | PLOS ONE
ide-cel and neurotoxicity | Int'l Myeloma Foundation
Next generation sequencing identifies smoldering multiple myeloma patients with a high risk of disease progression - ecancer
Post-Congress webinars – International Academy for Clinical Hematology (IACH)
Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber by Myeloma Crowd Radio | Mixcloud
